#United States #Robbins Geller #San Diego #Class Action #Lantheus Holdings

Lantheus Holdings Investors Urged to Take Action Amid Losses

In a critical announcement by Robbins Geller Rudman & Dowd LLP, investors who purchased or acquired securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025, and August 5, 2025, are being encouraged to step forward in a potential class action lawsuit. The deadline for individuals seeking to assume the role of lead plaintiff is November 10, 2025. This initiative arises due to substantial alleged losses sustained during this instructive period, underscoring the urgent need for collective legal action against the company.

Background of the Case

Lantheus Holdings, Inc. is recognized for its innovations in the pharmaceutical sector, specializing in the development, manufacture, and commercialization of diagnostic and therapeutic products for various diseases, notably cancer and heart conditions. The company’s flagship product, Pylarify, is a PET imaging agent pivotal for diagnosing and treating prostate cancer. However, recent disclosures have raised significant alarm regarding the company's transparency about its financial forecasts and operations.

According to the lawsuit filed in the Southern District of New York under the caption Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491, there are serious allegations against Lantheus and several of its top executives. The complaint accuses them of violating 1934 Securities Exchange Act provisions by allegedly providing misleading information regarding the company’s revenue projections while downplaying associated risks from market competition, seasonal dynamics, and macroeconomic changes.

Allegations of Misleading Information

The crux of the allegations states that Lantheus executives cultivated a false narrative regarding projected growth and efficiency in the sales of Pylarify. Despite confident forecasts, reality saw the sales trajectory falter. The class action complaint details a dramatic disclosure by Lantheus on May 7, 2025, when it publicly announced a decrease in year-over-year sales of Pylarify. This announcement was officially attributed to “temporal competitive disruption,” leading Lantheus to adjust its full-year projections significantly downward. The reaction was swift; Lantheus’s share price plummeted by more than 23% following the announcement.

Subsequently, on August 6, 2025, further disappointing results were disclosed, illustrating an alarming 8.3% decline in Pylarify's year-over-year performance and a more drastic cut to the 2025 fiscal year’s growth expectations. This has added urgency to the case, as this news precipitated a staggering 29% drop in the stock price, revealing the profound impact of the alleged misrepresentation on shareholders.

The Role of Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor impacted by these events during the class period can pursue the position of lead plaintiff in the resulting class action lawsuit. This role is typically assigned to the individual with the most significant financial interest in the class action and who is capable of adequately representing the collective interests of all affected investors. Those potentially interested in the lead plaintiff position should provide their details to Robbins Geller or contact them directly at 1-800-449-4900. Importantly, an individual’s eligibility to share in any recovery does not depend on their appointment as the lead plaintiff.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP stands as one of the preeminent law firms in the realm of securities fraud and shareholder litigation, securing notable outcomes for plaintiffs. With a formidable track record of obtaining over $2.5 billion for investors in securities class actions in 2024 alone, their expertise is widely recognized. The firm’s reputation is bolstered by a team of approximately 200 attorneys stationed across ten offices worldwide, consistently facilitating significant recoveries in high-stakes litigation, including landmark settlements in cases like the Enron scandal.

For those affected by the Lantheus situation, this class action represents a vital opportunity for accountability and potential recovery of losses. Further details about the ongoing litigation and how to participate can be found by visiting Robbins Geller’s dedicated webpage. As the legal landscape evolves, investors remain, no doubt, hopeful for justice.